|Bid||0.4750 x 3000|
|Ask||0.4980 x 900|
|Day's Range||0.4300 - 0.4949|
|52 Week Range||0.4100 - 2.2900|
|PE Ratio (TTM)||-0.39|
|Earnings Date||Mar 3, 2017 - Mar 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
SAN DIEGO, July 25, 2017-- Cytori Therapeutics, Inc., announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on July 19, 2017 to four new ...
NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Cytori Therapeutics saw its shares crushed on Monday, with the stock losing 56% at the close. Investors were disappointed with the company's preliminary data ...
Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday's trading session, after the biotech company disclosed that its pivotal STAR study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. Kolbert noted, "The totality of the data combined with the investigator comments matter and suggest to us that there maybe a window for approval based on the current data set and/or a small bridging study.